What Trump's 'most favoured nation' drug pricing policy might mean for Canadians

Trump's "most favoured nation" drug pricing policy aims to reduce U.S. pharmaceutical costs but experts warn it might lead to higher drug prices in other countries like Canada. Pharma companies could prioritize boosting U.S. profits by raising prices elsewhere to avoid triggering significant U.S. price cuts. This shift could have major implications for Canadian healthcare costs and access, highlighting the global impact of U.S. drug pricing strategies. The policy's broader effects on international drug pricing dynamics underscore the interconnectedness of global healthcare markets.